TOP NEWS: AstraZeneca's Beyfortus wins EU approval for RSV in newborns
(Alliance News) - AstraZeneca PLC on Friday said its respiratory syncytial virus treatment Beyfortus, or nirsevimab, which it develops with Sanofi SA, has received EU approval for prevention of the virus in newborns and infants. Read More